SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Files An 8-K Financial Statements and ExhibitsItem 9.01
|
ExhibitNo. |
Description of Exhibit |
| 99.1 | Press Release dated August10, 2017. |
SCICLONE PHARMACEUTICALS INC ExhibitEX-99.1 2 d438802dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Corporate Contacts Wilson W. Cheung Jane Green Chief Financial Officer Investors/Media 650.358.3434 650.358.1447 wcheung@sciclone.com jgreen@sciclone.com SCICLONE ANNOUNCES END OF GO-SHOP PERIOD WITH NO PARTIES DESIGNATED AS EXCLUDED PARTIES FOSTER CITY,…To view the full exhibit click here
About SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN)
SciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company’s lead product ZADAXIN (thymalfasin) is approved in approximately 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, the Company markets approximately seven partnered and in-licensed products in China. The Company’s development portfolio includes Angiomax, Neucardin, Loramyc, Cleviprex, RapidFilm, VIBATIV and SGX942. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL).